Sleep Disordered Breathing and Alzheimer's Disease Biomarkers in Normal Aging and Mild Cognitive Impairment
NCT ID: NCT03912571
Last Updated: 2021-09-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
28 participants
OBSERVATIONAL
2011-11-13
2019-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sleep Aging and Risk for Alzheimer's 2.0
NCT03278119
Assessment of Sleep Disturbance in Alzheimer Disease
NCT00831298
Biomarkers of Dementia in Chronic Sleep and Breathing Disorders
NCT06377332
Sleep, Aging and Risk for Alzheimer's Disease
NCT01962779
Sleep-dependent Learning in Aging
NCT03840083
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mild Cognitive Impairment (MCI)
Patients with clinical dementia rating of 0.5 or a global deterioration scale of 3.
VR-CO2 MRI Scans
reduced vaso reactivity to carbon dioxide
Structural 3T MRI
measures of global and hippocampal atrophy)
MRI Based Perfusion Imaging
brain blood flow
Normal Cognition (NL)
Clinical Dementia Rating \[CDR\] of 0 or Global Deterioration Scale \[GDS\] of 1-2
VR-CO2 MRI Scans
reduced vaso reactivity to carbon dioxide
Structural 3T MRI
measures of global and hippocampal atrophy)
MRI Based Perfusion Imaging
brain blood flow
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
VR-CO2 MRI Scans
reduced vaso reactivity to carbon dioxide
Structural 3T MRI
measures of global and hippocampal atrophy)
MRI Based Perfusion Imaging
brain blood flow
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Active depressive episode during the evaluation with a Geriatric Depression Scale score \>7 and/or a Clinical Global Impression scale for depression score \>4.
* Moderate Cognitive decline (GDS \>3).
* Severe primary or secondary insomnia except insomnia due to SDB.
55 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ricardo Osorio, MD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NYU Langone Medical Center
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
12-00041
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.